Working… Menu

An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04130997
Recruitment Status : Enrolling by invitation
First Posted : October 18, 2019
Last Update Posted : October 15, 2021
Information provided by (Responsible Party):
TG Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Enrolling by invitation
Estimated Primary Completion Date : October 2023
Estimated Study Completion Date : October 2023